Literature DB >> 7926461

Excess iron into hepatocytes is required for activation of collagen type I gene during experimental siderosis.

R Gualdi1, G Casalgrandi, G Montosi, E Ventura, A Pietrangelo.   

Abstract

BACKGROUND/AIMS: Liver fibrosis and cirrhosis represent common pathological findings in humans with iron overload. This study was undertaken to assess whether in vivo targeting of iron to liver parenchymal or nonparenchymal cells would differently affect collagen gene activity.
METHODS: Rats were treated with an iron diet or intramuscular injections of iron dextran, and in situ hybridization analyses on liver samples were performed.
RESULTS: These iron treatments determined parenchymal or reticuloendothelial cell iron overload, respectively. The typical distribution of iron into different liver cells was documented by histochemistry and confirmed by in situ hybridization analysis with a ferritin L complementary RNA probe. In iron-fed rats, in situ hybridization analysis identified a signal for collagen type I messenger RNA into nonparenchymal cells in zones I and II. In rats with nonparenchymal cell iron overload, no activation of collagen gene expression was detected into or near iron-laden nonparenchymal cells. These findings were also confirmed by quantitative Northern blot analysis.
CONCLUSIONS: The results of this study indicate that, regardless of the total hepatic iron burden, selective localization of iron into liver cells (i.e., parenchymal cells) is required for the activation of collagen gene during long-term iron overload in rodents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926461     DOI: 10.1016/0016-5085(94)90237-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

Review 1.  Molecular pathogenesis of iron overload.

Authors:  D Trinder; C Fox; G Vautier; J K Olynyk
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

2.  A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Paola Dongiovanni; Serena Rovida; Raffaela Rametta; Erika Fatta; Edoardo Alessandro Pulixi; Marco Maggioni; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

Review 4.  Current research of hepatic cirrhosis in China.

Authors:  Xi-Xian Yao; Shu-Lin Jiang; Dong-Mei Yao
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

5.  Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload.

Authors:  Gloria C Preza; Piotr Ruchala; Rogelio Pinon; Emilio Ramos; Bo Qiao; Michael A Peralta; Shantanu Sharma; Alan Waring; Tomas Ganz; Elizabeta Nemeth
Journal:  J Clin Invest       Date:  2011-12       Impact factor: 14.808

6.  Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin.

Authors:  Antonello Pietrangelo; Giuliana Montosi; Cinzia Garuti; Miranda Contri; Fabiola Giovannini; Daniela Ceccarelli; Alberto Masini
Journal:  J Bioenerg Biomembr       Date:  2002-02       Impact factor: 2.945

7.  Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents.

Authors:  A Pietrangelo; R Gualdi; G Casalgrandi; G Montosi; E Ventura
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations.

Authors:  Domenico Girelli; Ivana De Domenico; Claudia Bozzini; Natascia Campostrini; Fabiana Busti; Annalisa Castagna; Nadia Soriani; Laura Cremonesi; Maurizio Ferrari; Romano Colombari; Diane McVey Ward; Jerry Kaplan; Roberto Corrocher
Journal:  J Hepatol       Date:  2008-07-17       Impact factor: 25.083

9.  Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice.

Authors:  Claudia Mitchell; Marie-Anne Robin; Alicia Mayeuf; Meriem Mahrouf-Yorgov; Abdellah Mansouri; Marie Hamard; Dominique Couton; Bernard Fromenty; Hélène Gilgenkrantz
Journal:  Am J Pathol       Date:  2009-10-01       Impact factor: 4.307

Review 10.  PNPLA3 I148M polymorphism and progressive liver disease.

Authors:  Paola Dongiovanni; Benedetta Donati; Roberta Fares; Rosa Lombardi; Rosellina Margherita Mancina; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.